ArticleActa pharmacologica Sinica2016
Silibinin and indocyanine green-loaded nanoparticles inhibit the growth and metastasis of mammalian breast cancer cells in vitro.
Article in Acta pharmacologica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Comparative evaluation of the effects of Silymarin on the metastatic characteristics of MCF-7 and MDA-MB-231 breast cancer cells with two-dimensional and three-dimensional culture methods.BMC complementary medicine and therapies · 2026Article
- Comprehensive scientific insights on plant inspired nano therapeutics as the missing piece of the breast cancer puzzle.Discover nano · 2026Review
- A novel copper-based nanosystem for augmented breast cancer photothermal and chemodynamic therapy.RSC advances · 2026Article
- Sustained-Release Photothermal Microneedles for Postoperative Incisional Analgesia and Wound Healing via Hydrogen Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.Current pharmaceutical biotechnology · 2025Review
- Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer.Nanoscale advances · 2024Review
- Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage.Journal of nanobiotechnology · 2023Article
- Article
- Emerging indocyanine green-integrated nanocarriers for multimodal cancer therapy: a review.Nanoscale advances · 2021Review
- Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions.Journal of nanobiotechnology · 2020Article
- Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.Journal of nanobiotechnology · 2020Article
- Insight into the preformed albumin corona onAsian journal of pharmaceutical sciences · 2019Article
- Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.Chinese medicine · 2019Review
- Leveraging Engineering of Indocyanine Green-Encapsulated Polymeric Nanocomposites for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2018Review
- IR-780-loaded polymeric micelles enhance the efficacy of photothermal therapy in treating breast cancer lymphatic metastasis in mice.Acta pharmacologica Sinica · 2018Article
- Co-delivery of docetaxel and silibinin using pH-sensitive micelles improves therapy of metastatic breast cancer.Acta pharmacologica Sinica · 2017Article
- Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.Acta pharmacologica Sinica · 2017Article
- Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability.Drug design, development and therapy · 2017Article
- Anti-cancer effects of frankincense methanolic extract on brain metastatic breast cancer cells.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo improve the therapeutic efficacy of cancer treatments, combinational therapies based on nanosized drug delivery system (NDDS) has been developed recently. In this study we designed a new NDDS loaded with an anti-metastatic drug silibinin and a photothermal agent indocyanine green (ICG), and investigated its effects on the growth and metastasis of breast cancer cells in vitro.
methodsSilibinin and ICG were self-assembled into PCL lipid nanoparticles (SIPNs). Their physical characteristics including the particle size, zeta potential, morphology and in vitro drug release were examined. 4T1 mammalian breast cancer cells were used to evaluate their cellular internalization, cytotoxicity, and their influences on wound healing, in vitro cell migration and invasion.
resultsSIPNs showed a well-defined spherical shape with averaged size of 126.3±0.4 nm and zeta potential of -10.3±0.2 mV. NIR laser irradiation substantially increased the in vitro release of silibinin from the SIPNs (58.3% at the first 8 h, and 97.8% for the total release). Furthermore, NIR laser irradiation markedly increased the uptake of SIPNs into 4T1 cells. Under the NIR laser irradiation, both SIPNs and IPNs (PCL lipid nanoparticles loaded with ICG alone) caused dose-dependent ablation of 4T1 cells. The wound healing, migration and invasion experiments showed that SIPNs exposed to NIR laser irradiation exhibited dramatic in vitro anti-metastasis effects.
conclusionSIPNs show temperature-sensitive drug release following NIR laser irradiation, which can inhibit the growth and metastasis of breast cancer cells in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.